Virtu Financial LLC Invests $274,000 in BioNTech SE (NASDAQ:BNTX)

Virtu Financial LLC bought a new stake in BioNTech SE (NASDAQ:BNTX) in the 4th quarter, Holdings Channel.com reports. The fund bought 2,600 shares of the company’s stock, valued at approximately $274,000.

Other large investors have also recently added to or reduced their stakes in the company. Harding Loevner LP acquired a new position in shares of BioNTech during the 4th quarter valued at about $410,984,000. Clearbridge Investments LLC raised its stake in BioNTech by 41.6% during the third quarter. Clearbridge Investments LLC now owns 484,126 shares of the company’s stock worth $52,595,000 after purchasing an additional 142,344 shares during the period. Primecap Management Co. CA boosted its holdings in shares of BioNTech by 2.8% in the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after purchasing an additional 131,490 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of BioNTech by 43.1% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company’s stock worth $44,610,000 after buying an additional 127,951 shares during the last quarter. Finally, abrdn plc acquired a new stake in shares of BioNTech during the 4th quarter worth $10,961,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Stock Performance

NASDAQ:BNTX opened at $85.88 on Friday. The firm has a 50-day moving average of $92.67 and a two-hundred day moving average of $95.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. The stock has a market cap of $20.42 billion, a P/E ratio of 171.76 and a beta of 0.27. BioNTech SE has a 1-year low of $85.21 and a 1-year high of $125.83.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, May 6th. The company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The business had revenue of $203.69 million during the quarter, compared to analysts’ expectations of $589.96 million. On average, research analysts expect that BioNTech SE will post -2.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on BNTX shares. The Goldman Sachs Group dropped their price target on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 28th. UBS Group cut their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. BMO Capital Markets reduced their price target on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and issued a $113.00 price objective on shares of BioNTech in a research report on Monday, June 10th. Finally, JPMorgan Chase & Co. reduced their target price on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. One analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $111.70.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.